Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669272 | 0.86 | NPC1 (0.52) | ALDH1A1MAPK1L3MBTL1TDP1CYP4F2 | |
| SCHEMBL7060854 | 0.85 | PTGER4 (0.49) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL10716907 | 0.84 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL13948404 | 0.83 | CYP4F2 (0.73) | ALDH1A1TDP1CYP4F2CYP4A11LMNA | |
| SCHEMBL28662041 | 0.83 | TDP1 (0.54) | ALDH1A1MAPK1L3MBTL1TDP1CYP4F2 | |
| SCHEMBL25310377 | 0.82 | POLB (0.53) | ALDH1A1MAPK1L3MBTL1TDP1NPC1 | |
| SCHEMBL22513148 | 0.81 | CYP4F2 (0.50) | ALDH1A1MAPK1L3MBTL1TDP1CYP4F2 | |
| SCHEMBL16672131 | 0.81 | NPC1 (0.55) | ALDH1A1L3MBTL1LMNAPTGER4PTGER3 | |
| SCHEMBL304176 | 0.81 | TDP1 (0.78) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL24405103 | 0.81 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1TDP1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | ALDH1A1 372/4885MAPK1 2838/4885L3MBTL1 1177/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | ALDH1A1 372/4885MAPK1 2838/4885L3MBTL1 1177/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | ALDH1A1 461/4885MAPK1 2855/4885L3MBTL1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.